Cognition Therapeutics Inc Quick Ratio (CGTX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cognition Therapeutics inc   (NASDAQ: CGTX)

Cognition Therapeutics Inc 's Quick Ratio

CGTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Cognition Therapeutics Inc 's Cash & cash equivalent grew by 9.26 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Cognition Therapeutics Inc 's Quick Ratio to 6.24, above Cognition Therapeutics inc average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 54 other companies have achieved higher Quick Ratio than Cognition Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 588 to 608.

Explain Quick Ratio?
How much Cash & cash equivalents CGTX´s has?
What are CGTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CGTX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -55.92 % -44.72 % 24.97 % -47.63 % 13.22 %
Y / Y Cash & cash equivalent Change 216.6 % 89.49 % 47.19 % 78.7 % -62.35 %
Quick Ratio MRQ 6.24 5.14 2.64 5.91 0.87
CGTX's Total Ranking # 608 # 588 # 0 # 139 # 829
Seq. Current Liabilities Change -9.96 % -56.53 % 109.26 % -46.18 % 12.91 %
Seq. Cash & cash equivalent Change 9.26 % -15.43 % -6.42 % 266.14 % -34.61 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 55
Healthcare Sector # 258
Overall Market # 608


Quick Ratio Statistics
High Average Low
6.96 3.9 0.87
(Dec 31 2021)   (Jun 30 2025)




Financial Statements
Cognition Therapeutics Inc 's Current Liabilities $ 5 Millions Visit CGTX's Balance sheet
Cognition Therapeutics Inc 's Cash & cash equivalent $ 34 Millions Visit CGTX's Balance sheet
Source of CGTX's Sales Visit CGTX's Sales by Geography


Cumulative Cognition Therapeutics Inc 's Quick Ratio

CGTX's Quick Ratio for the trailling 12 Months

CGTX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -31.98 % -14.7 % -0.85 % -5.05 % 21.48 %
Y / Y Cash & cash equivalent TTM Growth 90.44 % 28.31 % -6.27 % -20.52 % -41.16 %
Quick Ratio TTM 4.4 3.03 2.35 2.23 1.57
Total Ranking TTM # 3687 # 2829 # 0 # 3044 # 1654
Seq. Current Liabilities TTM Growth -17.73 % -11.16 % 6.77 % -12.83 % 3.16 %
Seq. Cash & cash equivalent TTM Growth 19.72 % 14.23 % 12.9 % 23.35 % -19.34 %

Quick ratio ranking by company, industry and sector >> Back to CGTX Financial Strength Comparisons >> Go to Compare CGTX Quick Ratio to its Competitors

On the trailing twelve months basis CGTX Cash & cash equivalent more than doubled by 216.6 % in Q2 2026 year on year, while Current Liabilities decreased to $5 millions, this led to increase in in Cognition Therapeutics Inc 's Quick Ratio to 4.4, above CGTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 138 other companies have achieved higher Quick Ratio than Cognition Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2829 to 3687.

Explain Quick Ratio?
How much Cash & cash equivalents CGTX´s has?
What are CGTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 139
Healthcare Sector # 865
Within the Market # 3687


trailing twelve months Quick Ratio Statistics
High Average Low
5.99 3.76 1.57
(Jun 30 2022)   (Jun 30 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Biotechnology & Pharmaceuticals Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Aura Biosciences Inc   16.56 $ 323.840  Millions$ 19.560  Millions
Kalaris Therapeutics Inc   16.46 $ 143.865  Millions$ 8.738  Millions
Kyverna Therapeutics Inc   16.10 $ 367.021  Millions$ 22.802  Millions
Tectonic Therapeutic Inc   15.96 $ 227.068  Millions$ 14.224  Millions
Candel Therapeutics Inc   15.89 $ 201.565  Millions$ 12.685  Millions
Inhibikase Therapeutics Inc   15.50 $ 159.019  Millions$ 10.260  Millions
Voyager Therapeutics Inc   13.75 $ 229.369  Millions$ 16.685  Millions
Leonabio Inc   13.07 $ 102.167  Millions$ 7.817  Millions
Lenz Therapeutics Inc   12.82 $ 220.651  Millions$ 17.212  Millions
X4 Pharmaceuticals Inc  11.41 $ 220.874  Millions$ 19.366  Millions
Quince Therapeutics Inc   11.30 $ 116.000  Millions$ 10.262  Millions
Compass Therapeutics Inc   11.15 $ 179.879  Millions$ 16.128  Millions
Odyssey Therapeutics, Inc.  10.98 $ 310.575  Millions$ 28.295  Millions
Protara Therapeutics Inc  10.70 $ 142.494  Millions$ 13.319  Millions
Engene Therapeutics Inc   9.79 $ 266.320  Millions$ 27.209  Millions
Eikon Therapeutics Inc   9.61 $ 531.178  Millions$ 55.296  Millions
Zura Bio Limited  9.46 $ 205.134  Millions$ 21.690  Millions
4d Molecular Therapeutics Inc   9.16 $ 436.624  Millions$ 47.673  Millions
Fate Therapeutics Inc   8.44 $ 275.141  Millions$ 32.592  Millions
Monte Rosa Therapeutics Inc   8.32 $ 1,152.100  Millions$ 138.548  Millions
Cullinan Therapeutics Inc   8.23 $ 334.500  Millions$ 40.628  Millions
Prokidney Corp   7.99 $ 181.564  Millions$ 22.710  Millions
In8bio Inc   7.97 $ 17.956  Millions$ 2.254  Millions
Denali Therapeutics Inc   7.89 $ 710.471  Millions$ 90.083  Millions
Redwoods Acquisition Corp  7.69 $ 9.300  Millions$ 1.210  Millions
Cardiff Oncology Inc   7.04 $ 76.005  Millions$ 10.797  Millions
Black Diamond Therapeutics Inc   6.98 $ 110.506  Millions$ 15.843  Millions
Immunovant Inc   6.81 $ 797.798  Millions$ 117.102  Millions
Scholar Rock Holding Corp  6.81 $ 492.088  Millions$ 72.242  Millions
Fennec Pharmaceuticals Inc   6.66 $ 82.498  Millions$ 12.394  Millions

Date modified: 2026-09-08T17:05:34+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.